Genelux Investor Presentation Deck

Commercial Strategy Leverage partnership with GOG Foundation ● Partnerships GENELUX Preeminent US-based cooperative group in Gynecologic Oncology Composed of leading KOLS in the field Partners in the OnPrime/GOG-3076 Phase 3 registration trial Self Launch Olvi-Vec for Ovarian Cancer in the US ● ● 屈 Self-Manufacturing Large-Scale cGMP Manufacturing Control of Production Schedule Attractive COGS Ability to scale up modular process ● ● Patients Population without Standard of Care PRROC patients lack effective SoC therapies Limited number of Gyn- Oncs enabling specialty sales team Label expansion starting with IV administration in 2L ovarian (Ph2 planned) Compelling Value Proposition for Payors ● Reimbursement ● Significant unmet medical need No SOC Combination with generic/biosimilars 26

View entire presentation